Zobrazeno 1 - 10
of 81
pro vyhledávání: '"N, Mobashery"'
Autor:
Margaret Burroughs, Preethi Krishnan, N. Mobashery, Armen Asatryan, Wenjing Lu, Negar N. Alami, Qing Xie, Mingxiang Zhang, Wen Xie, Guiqiang Wang, Lai Wei, Jeong Heo, Jidong Jia, Hari V. Kalluri, Rakesh Tripathi, Seng Gee Lim, Jinlin Hou, Wei Liu, Linda M Fredrick, Yoon Jun Kim
Publikováno v:
SSRN Electronic Journal.
Background: Glecaprevir/pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data in non-Japanese Asian patients have been minimal. Methods: Two phase 3 studies
Autor:
Seng Gee Lim, N. Mobashery, Wei Liu, Yoon Jun Kim, Jidong Jia, Mingxiang Zhang, Jinlin Hou, Wenjing Lu, Lai Wei, Margaret Burroughs, Guiqiang Wang, Negar N. Alami, Rakesh Tripathi, Preethi Krishnan, Jeong Heo, Armen Asatryan, Linda M Fredrick, Qing Xie, Wen Xie, Hari V. Kalluri
Publikováno v:
The lancet. Gastroenterologyhepatology. 5(9)
Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been minimal. The aim of t
Autor:
Gamal Esmat, Reham Soliman, Naglaa Allam, N. Mobashery, Mohamed Hassany, Gamal Shiha, Sarah Kopecky-Bromberg, Negar N. Alami, Mohammad A. Mohey, Coleen Hall, Rabab Fouad, Roula B. Qaqish, Imam Waked
Publikováno v:
Journal of Medical Virology
In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This su
Autor:
Weihan Zhao, Bifeng Ding, Rajeev M. Menon, Jiuhong Zha, Katia Alves, Yan Luo, Haoyu Wang, N. Mobashery, Chen Yu
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 44:43-52
The 3 direct-acting antiviral (3D) regimen of ombitasvir/paritaprevir/ritonavir plus dasabuvir has recently been approved in several Asian geographic regions for the treatment of hepatitis C virus (HCV) genotype (GT) 1 infection. The pharmacokinetics
Autor:
Rakesh Tripathi, Tatyana Dekhtyar, Thomas Reisch, Coleen Hall, Tami Pilot-Matias, N. Mobashery, Yao Yu, Rebecca Redman, Christine Collins, Michelle Irvin, Gretja Schnell, Preethi Krishnan, Jill Beyer
Publikováno v:
Journal of Viral Hepatitis. 25:1078-1088
Hepatitis C virus (HCV) genotype 4 (GT4) is genetically diverse with 17 confirmed and 4 provisional subtypes. In this report, HCV GT4-infected patient samples from Phase 2/3 clinical studies were analysed to characterize global demographics and genet
Autor:
Peter Ferenci, Tami Pilot-Matias, N. Mobashery, Jordan J. Feld, George V. Papatheodoridis, Christophe Hézode, Christophe Moreno, Tarek Hassanein, Stefan Zeuzem, Yao Yu, Roula B. Qaqish, Rebecca Redman, Tarik Asselah, Magdy Elkhashab
Publikováno v:
The Lancet Gastroenterology & Hepatology. 1:25-35
Hepatitis C virus (HCV) genotype 4 infection is most commonly reported in sub-Saharan Africa and the Middle East; however, prevalence is increasing worldwide through immigration. HCV genotype 4 accounts for 20% of all infections, but clinical trial d
Autor:
Coleen Hall, Mohamed Hassany, Reham Soliman, N. Mobashery, Tarik Asselah, Rebecca Redman, Gamal Shiha, Roula B. Qaqish, Mohammad A. Mohey, Gamal Esmat, Ayman Yosry, Imam Waked, Wahid Doss, Naglaa Allam, Naglaa Zayed
Publikováno v:
The Lancet Gastroenterology & Hepatology. 1:36-44
In Egypt, chronic hepatitis C virus (HCV) infection occurs in around 10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis, hepatocellular carcinoma, and mortality. Although HCV genotype 4 constitutes about 20
Autor:
M. Gogishvili, T. Makharadze, P. Rietschel, H. Chen, P. Snodgrass, N. Mobashery, S. Lee, I. Lowy, M. Navarro
Publikováno v:
Journal of Thoracic Oncology. 14:S649
Autor:
Stanislas Pol, Coleen Hall, Katarzyna Fleischer-Stępniewska, Tarik Asselah, N. Mobashery, K. Rajender Reddy, Tami Pilot-Matias, Regis A. Vilchez, Gretja Schnell, Rebecca Redman, Christophe Hézode, Patrick Marcellin, Marina Berenguer, Tarek Hassanein
Publikováno v:
Lancet
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-o
Autor:
Rolando M Viani, Roger Trinh, Giuliano Rizzardini, Cristina Tural, Pierre-Marie Girard, Yiran B Hu, N. Mobashery, Hartwig H F Klinker, Linda M Fredrick, Edward Gane, Chloe Orkin, Nancy S. Shulman, David L. Wyles, Tami Pilot-Matias, Adriano Lazzarin, Jürgen K. Rockstroh, Sanjay Bhagani, Mark Nelson, Ruth Soto-Malave, Anne F Luetkemeyer
Publikováno v:
Open Forum Infectious Diseases
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background Ombitasvir, paritaprevir with ritonavir, and dasabuvir (OBV/PTV/r ± DSV) ±ribavirin (RBV) are approved to treat hepatitis C virus (HCV) genotype 1 and 4 infection. Here, we investigate the safety and efficacy of OBV/PTV/r + DSV ±RBV for